Pediatrics · 4 h ago
AAP report outlines pediatric COVID-19 vaccine recommendations for 2026–2027
An American Academy of Pediatrics technical report supports recommendations for COVID-19 vaccination during the 2026–2027 respiratory virus season. It reviews pediatric disease burden, vaccine effectiveness and safety, cost-effectiveness, and practical considerations for available products.
- Recommendations cover infants, children, and adolescents.
- All children aged 6–23 months are included.
- Additional groups aged 2–18 years are specified.
- Report reviews safety, effectiveness, and vaccine logistics.
The American Academy of Pediatrics (AAP) technical report accompanies its policy statement on COVID-19 vaccination for infants, children, and adolescents during the 2026–2027 respiratory virus season. It synthesizes evidence on SARS-CoV-2 epidemiology and disease burden in pediatric populations, as well as vaccine effectiveness, safety, and cost-effectiveness. The report also describes available vaccine products and formulations, storage and handling, and coadministration with other immunizations.
The accompanying recommendations support vaccination for all infants and children aged 6–23 months and for children aged 6 months through 18 years who are moderately or severely immunocompromised. For children aged 2–18 years, vaccination is also recommended for specified groups: those at high risk of severe COVID-19, residents of long-term care or other congregate settings, those never vaccinated against COVID-19, and those with household contacts at high risk of severe disease. The source provides no detailed effectiveness estimates, safety rates, or product-specific schedules. The full report was not available in the supplied material, so implementation details should be checked in the AAP policy statement and complete technical report.
In practice
The AAP report supports COVID-19 vaccination for all children aged 6–23 months and for moderately or severely immunocompromised children aged 6 months through 18 years. It also identifies additional groups aged 2–18 years, including those at high risk of severe disease, in congregate settings, previously unvaccinated, or living with high-risk household contacts. These are recommendations in an AAP technical report; the supplied material does not provide product-specific schedules, detailed safety or effectiveness estimates, or the full policy text, so those details cannot be assessed here.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Pediatrics: Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026–2027: Technical Report ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.